JP2022529262A5 - - Google Patents
Info
- Publication number
- JP2022529262A5 JP2022529262A5 JP2021560961A JP2021560961A JP2022529262A5 JP 2022529262 A5 JP2022529262 A5 JP 2022529262A5 JP 2021560961 A JP2021560961 A JP 2021560961A JP 2021560961 A JP2021560961 A JP 2021560961A JP 2022529262 A5 JP2022529262 A5 JP 2022529262A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- mitochondria
- approximately
- composition
- pieces
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962834020P | 2019-04-15 | 2019-04-15 | |
| US62/834,020 | 2019-04-15 | ||
| PCT/US2020/028219 WO2020214644A1 (en) | 2019-04-15 | 2020-04-15 | Aerosolized compositions comprising mitochondria and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529262A JP2022529262A (ja) | 2022-06-20 |
| JP2022529262A5 true JP2022529262A5 (https=) | 2023-04-25 |
| JP7590341B2 JP7590341B2 (ja) | 2024-11-26 |
Family
ID=72837565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021560961A Active JP7590341B2 (ja) | 2019-04-15 | 2020-04-15 | ミトコンドリアを含むエアロゾル化組成物及びその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220395531A1 (https=) |
| EP (2) | EP3955902B1 (https=) |
| JP (1) | JP7590341B2 (https=) |
| CN (1) | CN113905724A (https=) |
| ES (1) | ES2988040T3 (https=) |
| WO (1) | WO2020214644A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017124037A1 (en) | 2016-01-15 | 2017-07-20 | The Children's Medical Center Corporation | Therapeutic use of mitochondria and combined mitochondrial agents |
| WO2020222866A1 (en) * | 2019-05-02 | 2020-11-05 | Children's Medical Center Corporation | Prophylactic and therapeutic use of mitochondria and combined mitochondrial agents |
| WO2023191495A1 (ko) * | 2022-03-29 | 2023-10-05 | 주식회사 파이안바이오테크놀로지 | 동결 및 동결건조된 미토콘드리아 및 이의 용도 |
| CN119365073A (zh) * | 2022-06-10 | 2025-01-24 | 赛立维公司 | 用于冷冻保存线粒体的组合物和方法 |
| CN115634178A (zh) * | 2022-10-13 | 2023-01-24 | 广州华茜药业科技有限公司 | 补充机体细胞能量的线粒体组合物及其制备方法 |
| CN115624515A (zh) * | 2022-10-13 | 2023-01-20 | 广州华茜药业科技有限公司 | 一种抗皱抗衰的线粒体组合物及其应用 |
| WO2025184537A1 (en) * | 2024-03-01 | 2025-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Bio-engineered mitochondria for targeted delivery to cells |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3826255A (en) | 1972-06-22 | 1974-07-30 | Hudson Oxygen Therapy Sales Co | Intermittent positive pressure breathing manifold |
| YU41046B (en) | 1974-08-22 | 1986-10-31 | Schering Ag | Medicine inholating device |
| US4268460A (en) | 1977-12-12 | 1981-05-19 | Warner-Lambert Company | Nebulizer |
| US4253468A (en) | 1978-08-14 | 1981-03-03 | Steven Lehmbeck | Nebulizer attachment |
| DE3151275C2 (de) | 1981-12-24 | 1986-07-10 | SKF GmbH, 8720 Schweinfurt | Befestigungsvorrichtung für Werkzeuge |
| US4649911A (en) | 1983-09-08 | 1987-03-17 | Baylor College Of Medicine | Small particle aerosol generator for treatment of respiratory disease including the lungs |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| CN1133568C (zh) | 1999-01-18 | 2004-01-07 | 地球制药株式会社 | 气溶胶扩散喷雾器 |
| CA2480790A1 (en) * | 2002-04-01 | 2003-10-16 | Kazunori Murakami | Use of antithrombin iii in treating acute lung injury |
| US8616195B2 (en) * | 2003-07-18 | 2013-12-31 | Novartis Ag | Nebuliser for the production of aerosolized medication |
| CA2560415A1 (en) | 2004-03-29 | 2005-10-13 | The Procter & Gamble Company | Aerosol |
| US7431222B2 (en) | 2005-06-03 | 2008-10-07 | Monterrosa Christopher H | Aerosol spray masking device |
| IL183818A0 (en) | 2007-06-10 | 2007-10-31 | Shimon Harpaz | Uniformly abrasive confectionery product and process therefor |
| WO2012085833A1 (en) * | 2010-12-22 | 2012-06-28 | Koninklijke Philips Electronics N.V. | Nebulizer device |
| WO2014113638A1 (en) * | 2013-01-17 | 2014-07-24 | Aer Devices, Inc. | Multi-use albuterol maintenance therapy formulations and devices therefor |
| US20160113887A1 (en) * | 2014-06-05 | 2016-04-28 | The Regents Of The University Of California | Halogenated ether compounds and methods of inducing anesthesia |
| JP6355220B2 (ja) * | 2014-12-31 | 2018-07-11 | 台灣粒線體應用技術股▲扮▼有限公司Ｔａｉｗａｎ Ｍｉｔｏｃｈｏｎｄｒｉｏｎ Ａｐｐｌｉｅｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．，Ｌｔｄ． | 肺損傷を治療するための新規な医薬組成物及びその使用 |
| WO2017124037A1 (en) | 2016-01-15 | 2017-07-20 | The Children's Medical Center Corporation | Therapeutic use of mitochondria and combined mitochondrial agents |
| CA3093459A1 (en) * | 2018-05-31 | 2019-12-05 | Crititech, Inc. | Methods for isolating tumor-specific immune cells from a subject for adoptive cell therapy and cancer vaccines |
| KR20210065963A (ko) * | 2018-09-17 | 2021-06-04 | 에라스무스 유니버시티 메디컬 센터 로테르담 | 아데노좀 |
| BR112022001207A2 (pt) * | 2019-07-24 | 2022-03-15 | Luca Science Inc | Método de obtenção de mitocôndrias de células e mitocôndrias obtidas |
-
2020
- 2020-04-15 EP EP20790601.7A patent/EP3955902B1/en active Active
- 2020-04-15 US US17/603,646 patent/US20220395531A1/en active Pending
- 2020-04-15 WO PCT/US2020/028219 patent/WO2020214644A1/en not_active Ceased
- 2020-04-15 ES ES20790601T patent/ES2988040T3/es active Active
- 2020-04-15 JP JP2021560961A patent/JP7590341B2/ja active Active
- 2020-04-15 CN CN202080039304.2A patent/CN113905724A/zh active Pending
- 2020-04-15 EP EP24188510.2A patent/EP4461369B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022529262A5 (https=) | ||
| He et al. | A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases | |
| Kumar et al. | Intranasal drug delivery: A non-invasive approach for the better delivery of neurotherapeutics | |
| US8387895B2 (en) | Inhalation nebulizer | |
| Labiris et al. | Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications | |
| Laube | The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination | |
| JP2002539072A5 (https=) | ||
| Rubin et al. | Emerging aerosol drug delivery strategies: from bench to clinic | |
| Gaul et al. | Nanotechnology approaches to pulmonary drug delivery: Targeted delivery of small molecule and gene-based therapeutics to the lung | |
| Zheng et al. | Novel inhalation therapy in pulmonary fibrosis: principles, applications and prospects | |
| Kaur et al. | Advanced aerosol delivery devices for potential cure of acute and chronic diseases | |
| JP2006522135A5 (https=) | ||
| WO2017027387A1 (en) | Methods for the treatment of mast cell related disorders with mast cell stabilizers | |
| Hoekman et al. | Aerosol-stable peptide-coated liposome nanoparticles: A proof-of-concept study with opioid fentanyl in enhancing analgesic effects and reducing plasma drug exposure | |
| Fan et al. | Advances in inhaled nanoparticle drug delivery for pulmonary disease management | |
| Kumar et al. | Strategies and prospects of nasal drug delivery systems | |
| Zarogoulidis et al. | Defense mechanisms of the respiratory system and aerosol production systems | |
| Saalbach | Nasal and pulmonary routes of drug delivery | |
| Tronde | Pulmonary drug absorption: in vitro and in vivo investigations of drug absorption across the lung barrier and its relation to drug physicochemical properties | |
| Vanbever | Performance-driven, pulmonary delivery of systemically acting drugs | |
| Patidar et al. | A review on pulmonary drug delivery system | |
| Ibrahim et al. | Current advancements in nasopulmonary drug delivery systems | |
| Müller et al. | Inhalation pathway as a promising portal of entry: what has to be considered in designing new nanomaterials for biomedical application? | |
| Dastidar et al. | Drug delivery in respiratory diseases: Current opportunities, molecular and cellular mechanism, and future challenges | |
| Han et al. | Engineering Lipid Nanoparticles for Precision RNA Delivery: Design Principles, Targeting Strategies, and Clinical Prospects |